ArticleIn vivo (Athens, Greece)
Production and Characterization of Porous Fibroin Scaffolds for Regenerative Medical Application.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Silk-Derived 3D-Bioprinted Scaffolds for Neural Repair and Nerve Regeneration: A Comprehensive Review.Life (Basel, Switzerland) · 2026Review
- Biofunctionalization of silk fibroin scaffolds with enamel matrix protein and injectable platelet rich fibrin for soft tissue augmentation: an in-ovo study.International journal of implant dentistry · 2025Article
- Biodegradable Silk Fibroin Matrices for Wound Closure in a Human 3D Ex Vivo Approach.Materials (Basel, Switzerland) · 2024Article
- Nanocomposite Methacrylated Silk Fibroin-Based Scaffolds for Bone Tissue Engineering.Biomimetics (Basel, Switzerland) · 2024Article
- Doping of casted silk fibroin membranes with extracellular vesicles for regenerative therapy: a proof of concept.Scientific reports · 2024Article
- Silk Fibroin Materials: Biomedical Applications and Perspectives.Bioengineering (Basel, Switzerland) · 2024Review
- Copper-Epigallocatechin Gallate Enhances Therapeutic Effects of 3D-Printed Dermal Scaffolds in Mitigating Diabetic Wound Scarring.ACS applied materials & interfaces · 2023Article
- Dental Pulp Stem Cells for Salivary Gland Regeneration-Where Are We Today?International journal of molecular sciences · 2023Review
- Chemoprevention of Experimental Periodontitis in Diabetic Rats with Silk Fibroin Nanoparticles Loaded with Resveratrol.Antioxidants (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimSilk is a natural biomaterial with several superior features for applications in regenerative medicine. In the present study an optimized process for manufacturing porous scaffolds out of the silk protein fibroin was developed. MATERIALS AND
methodsThe silk protein fibroin was dissolved in Ajisawa's reagent and the resulting fibroin solution was used to produce scaffolds by means of freeze-thawing cycling. Porosity, pressure and stab resistance as well as degradation behavior were assessed in order to characterize the physical properties of the resulting scaffolds.
resultsThe resulting sponge-like fibroin scaffolds were highly porous while the porosity correlated inversely with the concentration of the starting fibroin solution. Increased initial fibroin concentrations of the scaffolds resulted in increased compressive and cannulation resistance. The majority of the fibroin scaffolds were digested by 1 mg/ml protease XIV in 3 weeks, indicating their biodegradability.
conclusionThe production of scaffolds made of varying fibroin concentrations by means of freeze-thawing, following dissolution using Ajisawa's reagent, provides a simple and straightforward strategy for adjusting the physical and chemical properties of fibroin scaffolds for various medical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.